Sorafenib Tosylate CAS 475207-59-1 Purity ≥99.0% (HPLC) API Factory High Quality
Ubonelelo ngezoRhwebo i-Sorafenib Tosylate kunye neziPhakathi eziNxulumeneyo:
I-Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
I-4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
I-4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
I-4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
| Igama leMchiza | Sorafenib Tosylate |
| Izithethantonye | Nexavar;4-[4-[3-[4-Chloro-3-(Trifluoromethyl)phenyl]ureido]phenoxy]-N-Methylpicolinamide 4-Methylbenzenesulfonate;4-[4-[[4-Chloro-3-(Trifluoromethyl)phenyl]carbamamido]phenoxy]-N-Methyl-2-Pyridinecarboxamide 4-Methylbenzenesulfonate;BAY 43-9006 Tosylate |
| Inombolo yeCAS | 475207-59-1 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | C21H16ClF3N4O3.C7H8O3S |
| Ubunzima beMolekyuli | 637.03 |
| Indawo yokunyibilika | 225.0 ukuba 230.0℃ |
| Inovakalelo | Ukungeva kuMoya, Ubushushu abuva |
| Ukunyibilika | I-Soluble kuManzi (<1 mg/ml) ku-25℃, i-DMSO (127 mg/ml) ku-25℃, kunye ne-Ethanol (<1 mg/ml) kwi-25℃ |
| Iimeko zokuthumela ngenqanawe | Indawo epholileyo kunye neyomileyo (2~8℃), Khusela ekukhanyeni |
| I-COA kunye ne-MSDS | Iyafumaneka |
| Beka ubomi kwishelufa | Iminyaka emi-2 ukuba igcinwe ngokufanelekileyo |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha | Iziphumo |
| Imbonakalo | Umgubo oMthubi oKhanyayo okanye oMhlophe | Iyahambelana |
| Ubunyulu / Indlela yokuHlalutya | ≥99.0% (HPLC) | 99.8% |
| Indawo yokunyibilika | 225.0 ~ 230.0℃ | Iyahambelana |
| Iintsimbi ezinzima | ≤10ppm | <10ppm |
| Ilahleko ekomisweni | ≤0.50% | 0.12% |
| Intsalela kwi-Ignition | ≤0.20% | 0.10% |
| Nakuphi na Ukungacoceki Okukodwa | ≤0.50% | Iyahambelana |
| Ukungcola ngokupheleleyo | ≤0.50% | Iyahambelana |
| NMR Spectrum | Iyahambelana neSakhiwo | Iyahambelana |
| Umgangatho woVavanyo | Umgangatho woShishino | Iyahambelana |
| Ukusetyenziswa | I-Sorafenib Tosylate (CAS: 475207-59-1) kunyango lwe-RCC kunye ne-HCC | |
Umqulu:Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwisitya esivaliweyo.Gcina kwindawo epholileyo, eyomileyo (2~8℃) kunye nendawo yokugcina impahla engenamoya kude nezinto ezingahambelaniyo.Khusela ukukhanya kunye nokufuma.
Ukuhambisa ngenqanawe:Zisa kwihlabathi liphela ngomoya, ngeFedEx / DHL Express.Ukubonelela ngokukhawuleza nangokuthembekileyo.
Iikhowudi zoMngcipheko 36/37/38 - Ukucaphukisa amehlo, inkqubo yokuphefumula kunye nesikhumba.
Inkcazo yoKhuseleko S28 - Emva kokudibana nolusu, hlamba ngokukhawuleza ngeesepha ezininzi.
S26 - Xa udibana namehlo, hlambulula ngokukhawuleza ngamanzi amaninzi kwaye ufune iingcebiso zonyango.
I-Sorafenib Tosylate (i-CAS: 475207-59-1) luhlobo olutsha lwechiza le-antitumor ekujoliswe kulo, laphuhliswa yi-German Bayer Pharmaceuticals, kwaye yabonisa umsebenzi owandayo we-antitumor kwiimvavanyo zezilwanyana zangaphambili.I-Sorafenib ifumaneka kwiipilisi ze-200-mg zolawulo lomlomo kwaye isetyenziselwa unyango lwe-RCC kunye ne-HCC.I-Sorafenib Tosylate inokuchaphazela ngaxeshanye iiseli zethumba kunye nemithambo yegazi.Inempembelelo ephindwe kabini ye-antitumor: inokuthintela iindlela zokudluliselwa komqondiso weseli elamlwa yi-RAF/MEK/ERK ukuthintela ngokuthe ngqo ukukhula kweseli yethumba, ngelixa ikwathintela i-VEGF kunye ne-platelet derived growth factor (PDGF) receptors ukuthintela ukubunjwa kwegazi elitsha lethumba. imikhumbi, ngaloo ndlela inqanda ngokungangqalanga ukukhula iseli ithumba.
I-Sorafenib Tosylate, igama lokurhweba i-Nexavar, yaveliswa okokuqala yi-Bayer Pharmaceuticals eJamani.I-Sorafenib Tosylate yi-multi-kinase inhibitor enokuthi isetyenziswe ukunyanga izifo ezifana nomhlaza.NgoDisemba ka-2005, yamkelwa yi-US FDA njengechiza lokuqala kunyango lomhlaza wezintso okwinqanaba eliphezulu.Ngo-Agasti ka-2009, yadweliswa ngokusemthethweni e-China ngemvume ye-State Food and Drug Administration.
I-Sorafenib Tosylate yi-tyrosine kinases (VEGFR kunye ne-PDGFR) kunye ne-RAF/MEK/ERK i-cascade inhibitors, esebenza ngaxeshanye kwi-Raf-1,wtBRAF kunye ne-V599EBRAF, kunye ne-IC50 ye-6 nM, i-22 nM kunye ne-38 nM, ngokulandelanayo.
I-Sorafenib Tosylate inokuthintela ngaxeshanye iindidi ze-kinases ezikhoyo kwiseli kunye ne-cell surface, kuquka i-RAF kinase, i-vascular endothelial growth factor receptor-2 (VEGFR-2), i-vascular endothelial growth factor receptor-3 (VEGFR-3), iplatelet. -i-derived growth factor receptor-β (PDGFR-β), i-KIT kunye ne-FLT-3.Ingabonwa ukuba i-sorafenib toluenesulfonate ineempembelelo ezimbini ezichasene nethumba.Ngakolunye uhlangothi, inokuthintela ngokuthe ngqo ukukhula kwe-tumor ngokuvimbela i-RAF / MEK / ERK indlela yokubonisa;kwelinye icala, inokuthintela i-VEGFR kunye ne-PDGFR.Kwaye uthintele ukwakheka kwe-tumor neovascularization, inqanda ngokungathanga ngqo ukukhula kweeseli zethumba.I-Sorafenib Tosylate lelona chiza lisebenza kakhulu kunyango lomhlaza wesibindi oqhubekayo ngolawulo lwenkqubo, kwaye iya kuba lelona chiza litsha eliqhelekileyo kunyango lwesi sifo.
I-Sorafenib Tosylate kanye-imihla ngemihla yokulawulwa komlomo we-tumor yezilwanyana zokufakelwa kwezilwanyana ibonise uluhlu olubanzi lwemisebenzi yokulwa ne-tumor, kubandakanywa umhlaza wekoloni, i-cancer cell carcinoma, umhlaza webele, i-melanoma, umhlaza we-pancreatic, i-leukemia kunye nomhlaza we-ovarian kunye ne-mouse renal cell carcinoma. imodeli, imodeli ye-RENCA.
